Researchers leveraged human epidermal-growth-factor receptor-2 (HER2) overexpression to engage antibody-dependent cellular phagocytosis through a combination of trastuzumab and anti-CD47 macrophage checkpoint immunotherapy.
[Proceedings of the National Academy of Sciences of the United States of America]
7992332
{7992332:Q6TSBSQB}
apa
50
1
164558
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
